Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2011-04-26
2011-04-26
Moore, Susanna (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C544S262000, C544S251000, C514S250000
Reexamination Certificate
active
07932257
ABSTRACT:
The present invention provides compounds having the formula:wherein A-B together represent one of the following structures:wherein one ofis a double bond, as valency permits; and R2, R4, X1A, X2A, X1B, X2B, L1, L2, Y and Z are as defined in classes and subclasses herein, and pharmaceutical compositions thereof, as described generally and in subclasses herein, which compounds are useful as inhibitors of protein kinase (e.g., Aurora), and thus are useful, for example, for the treatment of Aurora mediated diseases.
REFERENCES:
patent: 2980677 (1961-04-01), Druey et al.
patent: 5654307 (1997-08-01), Bridges
patent: 5723608 (1998-03-01), Yuan
patent: 5760028 (1998-06-01), Jadhav
patent: 5929046 (1999-07-01), McMurry
patent: 6043228 (2000-03-01), McMurry
patent: 6096724 (2000-08-01), McMurry
patent: 6214834 (2001-04-01), Jadhav
patent: 6288078 (2001-09-01), Walsh
patent: 6506762 (2003-01-01), Horvath
patent: 6552192 (2003-04-01), Hanus
patent: 7119200 (2006-10-01), Guzi et al.
patent: 7148228 (2006-12-01), Kasibhatla et al.
patent: 2001/0007867 (2001-07-01), Chen
patent: 2003/0187261 (2003-10-01), Havlicek
patent: 2004/0157851 (2004-08-01), Haddach et al.
patent: 2005/0059650 (2005-03-01), Jones
patent: 1475094 (2004-11-01), None
patent: WO 94/13668 (1994-06-01), None
patent: WO 95/19774 (1995-07-01), None
patent: WO 97/20843 (1997-06-01), None
patent: WO 97/23480 (1997-07-01), None
patent: WO 98/08847 (1998-03-01), None
patent: WO 98/43962 (1998-10-01), None
patent: WO 00/43394 (2000-07-01), None
patent: WO 00/53185 (2000-09-01), None
patent: WO 00/53602 (2000-09-01), None
patent: WO 01/23389 (2001-04-01), None
patent: WO 01/49688 (2001-07-01), None
patent: WO 03/055491 (2003-07-01), None
patent: WO 03/082872 (2003-10-01), None
patent: WO 2004/065392 (2004-08-01), None
patent: WO 2004/096810 (2004-11-01), None
patent: WO 2004/098698 (2004-11-01), None
patent: WO 2005/07658 (2005-01-01), None
patent: WO 2005/39506 (2005-05-01), None
patent: WO 2005/82865 (2005-09-01), None
Moravcova et. al. (Bioorg. Med. Chem. Lett. 2003, 13, 2989-2992).
Dhainaut, et al. “New Purines and Purine Analogs as Modulators of Multidrug Resistance”Journal of Medicinal Chemistry(1996), 39(20), 4099-4108.
Kim, et al. “Synthesis and biological evaluations of pyrazolo[3,4-d]pyrimidines as cyclin-dependent kinase 2 inhibitors”European Journal of Medicinal Chemistry(2003), 38(5), 525-532.
Quintela, et al. “6-Dimethylamino 1H-Pyrazolo[3,4-d]pyrimidine derivatives as new inhibitors of inflammatory mediators in intact cells”Bioorganic&Medicinal Chemistry(2003), 11(6), 863-868.
Quintela, et al. “Pyrazolopyrimidines: synthesis, effect on histamine release from rat peritoneal mast cells and cytotoxic activity”European Journal of Medicinal Chemistry(2001), 36(4), 321-332.
Oslob Johan D.
Yu Chul Hyun
Choate Hall & Stewart LLP
Huck Emilie Porter
Moore Susanna
Robidoux Andrea L. C.
Sunesis Pharmaceuticals, Inc.
LandOfFree
Substituted pyrazolo[4,3-d]pyrimidines as aurora kinase... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Substituted pyrazolo[4,3-d]pyrimidines as aurora kinase..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Substituted pyrazolo[4,3-d]pyrimidines as aurora kinase... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2694476